{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:42:15Z","timestamp":1766058135035,"version":"3.48.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-04164-6","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:19:18Z","timestamp":1764145158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening of the founder pathogenic variants BRCA1 and BRCA2 in Russian metropolitan women"],"prefix":"10.1186","volume":"25","author":[{"given":"Natalia","family":"Bodunova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Airat","family":"Bilyalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasiia","family":"Danishevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurami","family":"Kvetenadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artem","family":"Andronov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Starshinin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Rumyantsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Zhukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Khripun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Khatkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"9","key":"4164_CR1","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 2017;3(9):1190\u20136.","journal-title":"JAMA Oncol"},{"issue":"Supplementum2","key":"4164_CR2","first-page":"72","volume":"32","author":"J Soukupov\u00e1","year":"2019","unstructured":"Soukupov\u00e1 J, Lhotov\u00e1 K, Zem\u00e1nkov\u00e1 P, Vo\u010dka M, Janatov\u00e1 M, Stola\u0159ov\u00e1 L, et al. Contribution of massive parallel sequencing to diagnosis of hereditary ovarian cancer in the Czech Republic. Klin Onkol. 2019;32(Supplementum2):72\u20138.","journal-title":"Klin Onkol"},{"issue":"23","key":"4164_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, Ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"key":"4164_CR4","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated hereditary breast and ovarian cancer. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle: University of Washington, Seattle; 1998."},{"key":"4164_CR5","unstructured":"3NCCN. NCCN. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Cited 2024 June 14."},{"issue":"8","key":"4164_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1634\/theoncologist.2016-0135","volume":"21","author":"M Dhawan","year":"2016","unstructured":"Dhawan M, Ryan CJ, Ashworth A. DNA repair deficiency is common in advanced prostate cancer: new therapeutic opportunities. Oncologist. 2016;21(8):940\u20135.","journal-title":"Oncologist"},{"issue":"23","key":"4164_CR7","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.3390\/cancers14235953","volume":"14","author":"KH Buckley","year":"2022","unstructured":"5, Buckley KH, Niccum BA, Maxwell KN, Katona BW. Gastric cancer risk and pathogenesis in BRCA1 and BRCA2 carriers. Cancers. 2022;14(23):5953.","journal-title":"Cancers"},{"issue":"5","key":"4164_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/cge.12497","volume":"87","author":"V Sopik","year":"2015","unstructured":"6Sopik V, Phelan C, Cybulski C, Narod SA. BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet. 2015;87(5):411\u20138.","journal-title":"Clin Genet"},{"issue":"2","key":"4164_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3343\/alm.2020.40.2.114","volume":"40","author":"A Lee","year":"2020","unstructured":"Lee A, Moon BI, Kim TH. BRCA1\/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Annals Lab Med. 2020;40(2):114\u201321.","journal-title":"Annals Lab Med"},{"issue":"10","key":"4164_CR10","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.ejca.2006.01.050","volume":"42","author":"AP Sokolenko","year":"2006","unstructured":"Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer. 2006;42(10):1380\u20134.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4164_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1897-4287-7-5","volume":"7","author":"EN Suspitsin","year":"2009","unstructured":"Suspitsin EN, Sherina NY, Ponomariova DN, Sokolenko AP, Iyevleva AG, Gorodnova TV, et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered Cancer Clin Pract. 2009;7(1):5.","journal-title":"Hered Cancer Clin Pract"},{"issue":"2","key":"4164_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.canlet.2010.07.013","volume":"298","author":"AG Iyevleva","year":"2010","unstructured":"Iyevleva AG, Suspitsin EN, Kroeze K, Gorodnova TV, Sokolenko AP, Buslov KG, et al. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett. 2010;298(2):258\u201363.","journal-title":"Cancer Lett"},{"issue":"4","key":"4164_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","volume":"28","author":"J Mateo","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, Andr\u00e9 F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28(4):658\u201365.","journal-title":"Nat Med"},{"key":"4164_CR14","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Ardinger HH, Pagon RA, editors. GeneReviews\u00ae. Seattle: University of Washington, Seattle; 1993. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/. Cited 2024 May 21."},{"key":"4164_CR15","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2147\/CMAR.S189627","volume":"11","author":"C Forbes","year":"2019","unstructured":"Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019;11:2321\u201337.","journal-title":"Cancer Manag Res"},{"key":"4164_CR16","unstructured":"Final Recommendation Statement: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing | United States Preventive Services Taskforce. Available from: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/document\/RecommendationStatementFinal\/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing. Cited 2024 May 21."},{"key":"4164_CR17","first-page":"244","volume":"11","author":"VE Arayevna","year":"2020","unstructured":"Arayevna VE, Vladimirovich GO, Victorovich BA, Pesennikova EV, Kuchit EO. Analysis of miscarriage occurrence per population group. Syst Reviews Pharm. 2020;11:244\u20138.","journal-title":"Syst Reviews Pharm"},{"issue":"3","key":"4164_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/ajm.AJM_21_18","volume":"8","author":"RK Alaofi","year":"2018","unstructured":"Alaofi RK, Nassif MO, Al-Hajeili MR. Prophylactic mastectomy for the prevention of breast cancer: review of the literature. Avicenna J Med. 2018;8(3):67\u201377.","journal-title":"Avicenna J Med"},{"key":"4164_CR19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.18027\/2224-5057-2023-13-3s2-1-157-200","volume":"13","author":"SA Tyulyandin","year":"2023","unstructured":"Tyulyandin SA, Artamonova EV, Zhigulev AN. Practical recommendations of RUSSCO, part 1. Malignant Tumors. 2023;13:157\u2013200.","journal-title":"Malignant Tumors"},{"key":"4164_CR20","doi-asserted-by":"publisher","unstructured":"ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113(4):957\u2013966. https:\/\/doi.org\/10.1097\/AOG.0b013e3181a106d4. PMID: 19305347.","DOI":"10.1097\/AOG.0b013e3181a106d4"},{"issue":"1","key":"4164_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/jnci\/dju379","volume":"107","author":"R Manchanda","year":"2015","unstructured":"Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, et al. Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst. 2015;107(1):379.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"4164_CR22","first-page":"1349","volume":"56","author":"V Lemeshko","year":"2020","unstructured":"Lemeshko V, Tepcova T, Ratushnyak S, Musina. Assessment of the relevance of molecular genetic testing of mutations in Brca genes in patients with malignant neoplasms of the ovary 359 and breast. Genetica. 2020;56(12):1349\u201365.","journal-title":"Genetica"},{"issue":"3","key":"4164_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/cge.14098","volume":"101","author":"A Finch","year":"2022","unstructured":"Finch A, Metcalfe K, Akbari M, Friedman E, Tung N, Rosen B, et al. The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT. Clin Genet. 2022;101(3):317\u201323.","journal-title":"Clin Genet"},{"issue":"10","key":"4164_CR24","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/humu.20384","volume":"7","author":"M Buisson","year":"2006","unstructured":"Buisson M, Anczuk\u00f3w O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat. 2006;7(10):1024\u20139.","journal-title":"Hum Mutat"},{"issue":"3","key":"4164_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13353-011-0040-6","volume":"52","author":"I Brozek","year":"2011","unstructured":"Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, et al. Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet. 2011;52(3):325\u201330.","journal-title":"J Appl Genet"},{"issue":"2","key":"4164_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.acra.2022.03.030","volume":"30","author":"R Faermann","year":"2023","unstructured":"Faermann R, Friedman E, Kaidar-Person O, Brodsky M, Neiman OH, Shalmon A, et al. Pregnancy associated breast cancer among Israeli BRCA1\/BRCA2 carriers in a High-Risk clinic. Acad Radiol. 2023;30(2):248\u201354.","journal-title":"Acad Radiol"},{"issue":"6","key":"4164_CR27","doi-asserted-by":"publisher","first-page":"e0127363","DOI":"10.1371\/journal.pone.0127363","volume":"10","author":"F Kwiatkowski","year":"2015","unstructured":"Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon YJ. BRCA mutations increase fertility in families at hereditary Breast\/Ovarian cancer risk. PLoS ONE. 2015;10(6):e0127363.","journal-title":"PLoS ONE"},{"issue":"1","key":"4164_CR28","doi-asserted-by":"publisher","first-page":"20249999","DOI":"10.1515\/med-2024-9999","volume":"19","author":"M Dellino","year":"2024","unstructured":"Dellino M, D\u2019Amato A, Battista G, Cormio G, Vimercati A, Loizzi V, et al. Reproductive outcomes in women with BRCA 1\/2 germline mutations: A retrospective observational study and literature review. Open Med (Warsaw Poland). 2024;19(1):20249999.","journal-title":"Open Med (Warsaw Poland)"},{"issue":"6","key":"4164_CR29","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1086\/421442","volume":"74","author":"I Gal","year":"2004","unstructured":"Gal I, Sadetzki S, Gershoni-Baruch R, Oberman B, Carp H, Papa M, et al. Offspring gender ratio and the rate of recurrent spontaneous miscarriages in Jewish women at high risk for breast\/ovarian cancer. Am J Hum Genet. 2004;74(6):1270\u20135.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"4164_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.20892\/j.issn.2095-3941.2022.0593","volume":"20","author":"J Liu","year":"2023","unstructured":"Liu J, Yao L, Sun J, Hu L, Chen J, Zhang J, et al. Cancer risk in relatives of BRCA1\/2 pathogenic variant carriers in a large series of unselected patients with breast cancer. Cancer Biol Med. 2023;20(2):147\u201354.","journal-title":"Cancer Biol Med"},{"issue":"23","key":"4164_CR31","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"20","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, Ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. Jun 2017;20(23):2402\u201316.","journal-title":"JAMA"},{"issue":"3","key":"4164_CR32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10549-015-3419-y","volume":"151","author":"TS Menes","year":"2015","unstructured":"Menes TS, Terry MB, Goldgar D, Andrulis IL, Knight JA, John EM, et al. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the breast cancer family registry. Breast Cancer Res Treat. 2015;151(3):653\u201360.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"4164_CR33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jamaoncol.2023.5468","volume":"10","author":"A Bolze","year":"2024","unstructured":"Bolze A, Cirulli ET, Hajek C, Schnell Blitstein JM, Grzymski JJ. The potential of genetics in identifying women at lower risk of breast cancer. JAMA Oncol. 2024;10(2):236\u20139.","journal-title":"JAMA Oncol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-04164-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:37:31Z","timestamp":1766057851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-025-04164-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4164"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-04164-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"type":"electronic","value":"1472-6874"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Local Ethics Committee of the Moscow Clinical Scientific Center named after A. S. Loginov. Approval code: #12044. Approval date: 14,16 February 2018. Informed consent of all participants was obtained. Study procedures followed were in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"601"}}